fda glp-1 news november 2025 Pipeline Update: May - Prime Therapeutics What Patients Need to Know

FOXO4-DRI represents a transformative breakthrough in senescence research that has fundamentally changed our understanding of cellular aging and opened unprecedented opportunities for studying age-related diseases and interventions

[PubMed: 21824127] [CrossRef] 38

FEBS Lett 2005

Topical evidence is stronger and includes IRB-approved human trials

Promote a Brighter, More Radiant Complexion: Users often report a significant improvement in skin luminosity, contributing to an overall youthful glow

"There is, therefore, a clear need for interventions that address the stigma associated with using GLP-1s for weight loss." This article originally appeared on USA TODAY: GLP-1 users face increased judgment for weight-loss, study finds